Author

Arshi Arora

Primary ORCID profile (0000-0002-4040-1787 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Arshi AroraiD2 papers · Memorial Sloan Kettering Cancer Center

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Aamir Dohadwala· 1 shared Adriana Roopnariane· 1 shared Celia Andreu· 1 shared Chaithanya P. Vedula· 1 shared David Southwell· 1 shared Nazario Bosco· 1 shared Neil J. GanemiD· 1 shared Samuel F. W. BakhoumiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aamir Dohadwala

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

KIF18A Inhibition as a Therapeutic Strategy in Cancers with Rb Pathway Inactivation

Celia Andreu, Arshi Arora, Song Chen, Chaithanya P. Vedula, Adriana Roopnariane, Sarah E. Bettigole, Nazario Bosco, Aamir Dohadwala, the SOVI-2302 Investigators, The VLS-1488-2201 Investigators, David Southwell, Neil J. Ganem, Timothy Geoffrey Bowler, Samuel F. W. Bakhoum

This paper identifies p16INK4a expression as a predictive biomarker for KIF18A inhibitor response in cancers with Rb pathway inactivation, showing higher response rates and longer progression-free survival in p16INK4a-high tumors.

bioRxiv · Apr 20, 2026 · PreprintCancer Biology